China Medical University Hospital (Taiwan) and Shine-On Biomedical Co. developed SOB100, the world's first HLA-G targeted ...

MEDSIR announces positive results from TUXEDO-3 trial of patritumab deruxtecan in patients with active brain metastases and leptomeningeal disease: Chicago Monday, June 9, 2025, 1 ...

Dr. Chung brings over three decades of experience spanning clinical ophthalmology, academic research and gene therapy developmentLONDON and CAMBRIDGE, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Beacon T ...

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe PRINCETON, N.J., ...

A migraine drug commonly used to treat headache pain may also alleviate the early, non-pain symptoms that often precede a ...

Industry experts gathered at the Outsourcing in Clinical Trials East Coast 2025 conference to discuss artificial intelligence ...

Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...

LOS ANGELES, June 9, 2025 /PRNewswire/ — TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the ...

While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease ...

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its ...